share_log

EF Hutton Reiterates Buy on Atara Biotherapeutics, Maintains $25 Price Target

Benzinga ·  Aug 9, 2023 07:26

EF Hutton analyst Anthony Butler reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment